Journal
JOURNAL OF NEUROLOGY
Volume 269, Issue 10, Pages 5319-5327Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00415-022-11171-2
Keywords
Multiple sclerosis; Primary progressive multiple sclerosis; Clinical trial; MRI; Contrast-enhancing lesions; Outcome measure
Categories
Ask authors/readers for more resources
This study found that using timed 25-foot walk (T25FW) as the primary outcome measure might be more useful than the Expanded Disability Status Scale (EDSS) in clinical trials for primary progressive MS (PPMS), and using T25FW could shorten the duration of clinical trials. Additionally, the presence of contrast-enhancing lesions (CELs) at baseline was associated with disability outcomes.
Background Clinical trials in primary progressive MS (PPMS) generally use the Expanded Disability Status Scale (EDSS) as their primary outcome measure, although different clinical outcomes may be more useful. Disability worsening in PPMS trials may be influenced by baseline factors, such as age, sex, and contrast-enhancing lesions. Methods We used the dataset of PROMISE, a large randomized controlled trial of glatiramer acetate (GA) versus placebo, to compare the clinical outcomes EDSS, timed 25-foot walk (T25FW), and nine-hole peg test (NHPT). We used Cox regression analyses to investigate the association of the baseline factors age, sex, treatment arm, contrast-enhancing lesions (CELs), and EDSS on the time to 3-month confirmed disability worsening (3MCDW) on the EDSS and the T25FW. Results PROMISE included 943 participants. Worsening on the T25FW or EDSS or occurred much more frequently than on the NHPT. Having CELs at baseline was associated with a shorter time to 3MCDW on both the EDSS and T25FW. An additional resampling experiment using the PROMISE dataset showed that increasing representation of participants with CELs at baseline increases the likelihood of having a positive trial result in favor of GA treatment. Conclusion Our investigation suggests that the T25FW may be a more useful primary outcome measure than the EDSS in PPMS trials, and that its use may shorten clinical trials. Our findings on the impact of CELs at baseline on disability outcomes inform the critical appraisal of clinical trials in PPMS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available